全文获取类型
收费全文 | 326220篇 |
免费 | 15098篇 |
国内免费 | 10162篇 |
专业分类
耳鼻咽喉 | 2417篇 |
儿科学 | 8437篇 |
妇产科学 | 5559篇 |
基础医学 | 33369篇 |
口腔科学 | 4353篇 |
临床医学 | 32078篇 |
内科学 | 54330篇 |
皮肤病学 | 2364篇 |
神经病学 | 24156篇 |
特种医学 | 14130篇 |
外国民族医学 | 75篇 |
外科学 | 44002篇 |
综合类 | 27320篇 |
现状与发展 | 34篇 |
一般理论 | 11篇 |
预防医学 | 28143篇 |
眼科学 | 6952篇 |
药学 | 25565篇 |
164篇 | |
中国医学 | 9311篇 |
肿瘤学 | 28710篇 |
出版年
2024年 | 540篇 |
2023年 | 2399篇 |
2022年 | 6223篇 |
2021年 | 7827篇 |
2020年 | 5746篇 |
2019年 | 5063篇 |
2018年 | 26621篇 |
2017年 | 21801篇 |
2016年 | 23560篇 |
2015年 | 7525篇 |
2014年 | 9077篇 |
2013年 | 8699篇 |
2012年 | 18226篇 |
2011年 | 33080篇 |
2010年 | 26345篇 |
2009年 | 17665篇 |
2008年 | 27389篇 |
2007年 | 29478篇 |
2006年 | 8417篇 |
2005年 | 9716篇 |
2004年 | 8605篇 |
2003年 | 9210篇 |
2002年 | 6696篇 |
2001年 | 3940篇 |
2000年 | 4006篇 |
1999年 | 3843篇 |
1998年 | 2584篇 |
1997年 | 2473篇 |
1996年 | 1722篇 |
1995年 | 1637篇 |
1994年 | 1445篇 |
1993年 | 930篇 |
1992年 | 1304篇 |
1991年 | 1187篇 |
1990年 | 1078篇 |
1989年 | 910篇 |
1988年 | 776篇 |
1987年 | 723篇 |
1986年 | 545篇 |
1985年 | 509篇 |
1984年 | 276篇 |
1983年 | 201篇 |
1982年 | 146篇 |
1981年 | 123篇 |
1980年 | 115篇 |
1979年 | 124篇 |
1978年 | 67篇 |
1976年 | 61篇 |
1974年 | 84篇 |
1938年 | 61篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
日间手术在国外已有上百年的发展历史,现已成为欧美国家重要手术模式。我国于20世纪初开始开展日间手术,但目前尚未普及,发展不平衡问题比较突出,存在认识不清、开展不规范、与医保支付对接不畅等问题。日间手术是一种使国家、医院和病人三方均受益的新型手术模式。近年来,国家相关管理部门积极引导,开展日间手术的医院明显增多,可以预见,我国日间手术即将进入快速发展的新阶段。因此,有条件的医院可以从简单、易操作的病种开始,落实临床路径,积累经验,再逐步稳妥展开。在保证质量的前提下,不断拓展日间手术范围,提高三、四级手术比例。同时,积极与医保支付政策对接,采取灵活的方式,获得医保的支持,更好地促进我国日间手术的快速发展。 相似文献
42.
43.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
44.
45.
M. Alexandra Friedman Charlotte M. Niznik Janelle R. Bolden Lynn M. Yee 《Journal of community health》2016,41(2):354-358
While peer support has been investigated in multiple clinical contexts, its application to the postpartum setting is unknown. The aim was to assess acceptability of a postpartum peer support program for women with diabetes. Observational survey-based needs assessment of forty low-income women with diabetes, receiving care at a major medical institution. Mean age and gravidity were 30.7 years and 3.15 ± 1.67 respectively. 45 % expressed interest in a “buddy.” There was no significant difference between groups desiring and not desiring this program. A majority of respondents desired telephone, text messaging, and in-person contacts (79.2, 72.1, 83.8 %), with 72.5 % of patients desiring diabetes-related activities during clinic waiting time. Many women desire a postpartum diabetes reciprocal peer program for support outside of clinician visits. Patients are receptive to educational services during their wait and outside of clinic time, a potentially valuable opportunity to share important health information. 相似文献
46.
47.
Metabolic Brain Disease - Bupleurum chinense DC. (Chaihu) is a traditional Chinese medicine (TCM) used in the treatment of anxiety. But the anxiolytic mechanisms of bupleurum are still unclear.... 相似文献
48.
Haonan Guo Rui Zhang Justice Afrifa Yuanyuan Wang Jingcui Yu 《Pathology, research and practice》2019,215(6):152403
PurposeWe previously demonstrated that the functional inactivation of DAL-1 and TOB1 promotes an aggressive phenotype in gastric cancer cells, but the links between both genes and the survival of patients with gastric cancer are unknown. Here, we investigated the correlations of the expression levels of DAL-1 and TOB1 with the progression of gastric cancer.MethodsA total of 270 patients who underwent resectable gastrectomy were included. The expression of DAL-1 and TOB1 was detected by immunohistochemistry.ResultsLow expression of DAL-1 in cancer tissue was significantly associated with tumor site (p < 0.05), histological grade (p < 0.01), depth of invasion (p < 0.05), lymph node metastasis status (p < 0.05), Lauren classification (p < 0.001), and clinical stage (p < 0.01). A lower level of TOB1 was observed in gastric cancer patients with diffuse type disease compared to patients with either intestinal or mixed type disease (p < 0.001). Additionally, Spearman’s correlation analysis revealed that decreased expression of DAL-1 was positively correlated with low TOB1 expression (r=0.304, p < 0.001). The survival analysis showed that low levels of DAL-1 and TOB1 were significantly associated with poor survival of gastric cancer patients (p <0.001 and p < 0.05, respectively).ConclusionThe downregulation of DAL-1 and TOB1 expression is associated with shorter survival of gastric cancer patients. Hence, DAL-1 and TOB1 may be considered potential novel markers for predicting the outcomes of patients with gastric cancer. 相似文献
49.
Ju Zou Daichao Wu Tao Li Xianwen Wang Yan Liu Sijie Tan 《Pathology, research and practice》2019,215(2):229-234
Programmed death ligand 1(PD-L1) mediated immune escape play important roles in the development of cancer. The gene polymorphism of PD-L1, in particular rs4143815 C?>?G, has been associated with the cancer risks, but with conflicting results. Therefore, this meta-analysis was aimed to assess the association between rs4143815 C?>?G and cancer susceptibility. A systematic literature search was performed to select the studies and the pooled odds ratio (OR) with 95% confidence interval (CI) was used to evaluate the strength of association. Eleven eligible studies containing 3711 cases and 3704 controls were enrolled in the meta-analysis. The results suggested that there is a strong association between rs4143815 C?>?G and the cancer risks (G vs. C: OR?=?1.386, 95% CI: 1.132–1.696, p?=?0.002; GG vs. CG?+?CC: OR?=?1.843 95% CI: 1.300–2.613, p?=?0.002; GG?+?CG vs. CC: OR?=?1.280, 95% CI: 1.040–1.576, p?=?0.020). Subgroup analysis based on cancer type suggested that PD-L1 rs4143815 C?>?G might increase the susceptibility to gastric cancer (G vs. C: OR?=?1.842, 95% CI: 1.403–2.418, p?<?0.001) and bladder cancer (G vs. C: OR?=?2.015, 95% CI: 1.556–2.608, p?<?0.001), and genotype GG carriers of PD-L1 rs4143815 C?>?G might have higher risks of HCC (GG vs. CG?+?CC: OR?=?2.226 95% CI: 1.562–3.172, p?<?0.001). PD-L1 rs4143815 C?>?G might confer an increased cancer risk, indicating this SNP may contribute to the pathogenesis of cancer and might be used as a potential biomarker to predict the susceptibility to cancer. 相似文献